Editas Medicine Investor Relations Material
Latest events
Strategy Update
Editas Medicine
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Editas Medicine Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
Collaboration and other research and development revenues
Expenses by
Financials
Editas Medicine, a genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company seeks to address the fundamental flaws in existing approaches to genetic and infectious diseases by developing TALEN and CRISPR genome editing systems that function more efficiently than existing technologies. It has invented lymphocyte-directed gene therapy that uses CRISPR/Cas9 technology to manufacture a novel endonuclease. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Key slides for Editas Medicine Inc
Corporate Presentation
Editas Medicine Inc
Corporate Presentation
Editas Medicine Inc
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
EDIT
Country
🇺🇸 United States